)
KORU Medical Systems (KRMD) investor relations material
KORU Medical Systems Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic growth drivers
Achieved over 20% year-to-date growth, driven by international expansion and prefill technology adoption.
U.S. business outperformed the market, with primary immune deficiency patient growth of 8%-10% and U.S. revenue up 10%-15%.
Four new drugs expected to be added to the label between early and mid-2026, expanding patient reach.
Oncology pilot study showed 97% nurse preference, with a 510(k) submission by year-end and market launch in H2 2026.
New pump filing anticipated in H1 2026, targeting incremental share and higher ASP in both U.S. and international markets.
Market outlook and opportunities
U.S. SCIg market projected to grow 8%-10%, with only 20% of patients on subcutaneous therapy, leaving significant room for conversion.
Secondary immunodeficiency trials by all major players expected to conclude in 2027, potentially doubling the addressable patient population.
European market growth driven by prefill expansion, with five new markets expected to convert in 2026, two of which are larger than the initial converted market.
International segment projected to grow over 30% in 2026, with prefill expansion as a key lever.
Competitive landscape
U.S. competition centers on a single mechanical pump competitor, while Europe is dominated by electronic pumps that lack compatibility with prefills.
In the large-volume subcutaneous space, the main competitor is Enable, but the platform offers lower cost per use and a larger installed base.
More competitors are seen as positive for driving adoption of subcutaneous therapy.
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit hit ₹21,028.15 crore, driven by robust growth and strategic divestments. - 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next KORU Medical Systems earnings date
Next KORU Medical Systems earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)